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Anal cancer patients who have exhibited disease progression after having received all approved drugs pose a major therapeutic
challenge. In addition to cytotoxic agents, novel targeted agents are being developed and have an established role in the treatment
of many solid tumors, including colon cancer. However, their role in anal cancer is yet to be determined. Most anal malignancies
are squamous cell carcinomas often strongly expressing epidermal growth factor receptors (EGFRs). Targeting the latter seems
to result in favorable changes in tumor growth. We present three cases of refractory anal cancers, treated with EGFR inhibitors,
after having received the recommended chemotherapy regimens. We conclude that EGFR inhibitors may play a vital role in the
treatmentofanalcancerandwesuggestthatlargetrialsarebeconductedinordertoclarifytheireﬃcacyandtoimprovetherapeutic
management.
1.Introduction
Anal canal carcinoma (ACC) is a relatively rare gastrointesti-
nalmalignancy[1,2],anditsmostcommonhistologicaltype
issquamouscellcarcinoma[3].Five-yearsurvivalratesrange
from 78% in patients with local stage disease to only 18% in
patients with distant metastases [1].
Historically, abdominoperineal resection (APR) was
thought to be the standard treatment for nearly all anal
cancers below the dentate line, with an approximate 70% 5-
year survival [4].The currentstandard treatment forinvasive
anal carcinoma is the combination of radiotherapy and
chemotherapy. The 5-ﬂuorouracil (5-FU) plus mitomycin C
doublet combined with radiotherapy has been shown to be
more eﬀective than radiotherapy alone [5]a sw e l la sc o m -
pared to radiotherapy plus 5-FU [6]. However, mitomycin
C-related adverse events, such as hematological toxicity [7],
oftenleadtodiscontinuation ofthisdrugmakingitnecessary
to ﬁnd less toxic but equally eﬀective regimens. Other thera-
peutic options, such as targeted agents, need to be explored.
The epidermal growth factor receptor (EGFR) (also
known as HER-1 or c-erbB-1) is a glycoprotein that consists
of an extracellular receptor, a transmembrane region, and an
intracellular domain functioning as tyrosine kinase. There
are 40,000 to 100,000 EGFR receptors per normal cell,
whereas EGFR has been found overexpressed in most solid
tumors, such as nonsmall cell lung, renal, ovarian, head
and neck, and breast cancers [8]. It has been hypothesized
that EGFR overexpression increases signal generation and
activates downstream pathways making cells grow more
aggressively and develop invasive characteristics [9]. There
are two major categories of anti-EGFR therapeutics: anti-
bodies binding to the extracellular ligand-binding region
and small-molecule tyrosine-kinase inhibitors (TKIs) that
compete with ATP for binding to the kinase domain [10].
The Food and Drug Administration (FDA) has approved
the monoclonal antibodies cetuximab and panitumumab in
the treatment of colorectal and head and neck cancer and2 Journal of Oncology
erlotinib for lung and pancreatic cancer [10]. Finding EGFR
overexpressed in ACC has triggered interest to investigate
whether patients beneﬁt from such targeted therapies.
In a study that examined tissue samples of 21 patients
withACC,itwas foundthatallsamples had4+EGFRexpres-
sion while they were negative for HER-2 [11]. In another
study concerning 38 squamous cell carcinomas of the anal
canal (31 biopsies and 7 resection specimens) collected from
1989 to 2003, 55% of tumors showed EGFR immunoreactiv-
ity. 62% of the latter had moderate to strong EGFR expres-
sion [12]. Since none of cases showed EGFR gene ampli-
ﬁcation, other mechanisms such as activating mutations,
increased coexpression of receptor ligands, decreased recep-
tor turnover, and heterodimerization with other heterolo-
gousreceptorsystems such asHER-2 might be involved[13].
We present three cases of ACC patients who were
administered anti-EGFR therapy after having received the
recommended chemotherapeutic regimens.
2.CasePresentation(Table1)
2.1. Case 1. The ﬁrst patient was a 73-year-old Caucasian
female referred to us for salvage therapy. The patient had
recurrent squamous cell carcinoma of the anorectal junction
with lymph node metastases. The disease had recurred
after cisplatin, 5-FU, and radiation therapy. The computed
tomography scan (CT)showed abdominalas well as inguinal
lymphadenopathy. Carcinogenic embryonic antigen (CEA)
levels were 317ng/mg. After giving a fully informed consent,
she was administered cetuximab at an initial dose of
400mg/m2 followed by weekly doses of 250 mg/m2.I n
addition, she received mitomycin (10mg/m2)o nd a y1o f
each28-daycycle.Withtheexceptionofagrade2cetuximab-
related rash, the doublet was well-tolerated until week 12
whenmitomycinhadtobestoppedduetoseverethrombocy-
topenia and hemolytic-uremic syndrome (HUS). According
to new CT scans, the disease was stable (with a 17% decrease
in the size of the abdominal lymph nodes) and CEA levels
dropped to 214ng/mg. After the HUS was resolved, therapy
wascontinuedforanadditional4cycles(8weeks)butamag-
netic resonance imaging (MRI) scan (CT was not performed
due to concerns about contrast aﬀecting renal function
following recent HUS) revealed a 30% increase in the left
inguinal mass. CEA levels reached 1370ng/ml. We added
irinotecan to the regimen and this doublet kept the disease
stable for 11 cycles (5.5 months) up until an inguinal lymph
node started to become enlarged and painful. The patient
underwent palliative radiation therapy and later received
modiﬁed FOLFOX-7 regimen. She died 3 months later.
2.2. Case 2. A 64-year-old Caucasian male presented to our
clinic with the diagnosis of anal cancer with hepatic, lymph
node and bone metastases. His disease had progressed after
1st line treatment of 5-FU, mitomycin C and radiation
therapy and 2nd line cisplatin plus irinotecan. Cetuximab
was oﬀeredas salvage therapy at an initial doseof 400mg/m2
followed by weekly doses of 250mg/m2 and the patient
received 8 weekly courses. The treatment was generally well-
tolerated with the patient experiencing nausea grade 2,
diarrhea grade 1 and rash grade 2. Restaging CT scans and
bone scanning revealed that the disease was stable but the
bone metastases’ pain had increased. The patient chose to
continue with palliative radiation therapy.
2.3. Case 3. The third patient was a 51-year-old African
American male who had received ACC initial treatment
consisting of mitomycin C, 5-FU and radiation therapy.
The disease recurred 1.5 years later, and the patient received
FOLFOX with further progression to abdominal lymph
nodes. A severe hypersensitivity reaction was observed
during the initial infusion of cetuximab, and the patient
was oﬀered panitumumab monotherapy (6mg/kg). After
receiving four doses, he developed a grade 3 rash. He was
treated with emollients, oral minocycline, and the dose was
reduced to 4.5mg. This dose was well tolerated, and we re-
escalated back to the full dose of 6mg within the next week.
Disease progression was noted after a total of 12 cycles of
panitumumab treatment (6 months).
3.EGFRand KRASStatus
EGFR status was retrospectively tested by immunostain-
ing, and KRAS genotyping was performed by using poly-
m e r a s ec h a i nr e a c t i o n( P C R )w i t he x o n1ﬂ a n k i n gp r i m e r s
followed by single-strand conformational polymorphism
(SSCP)analysis. AllthreepatientshadEGFR-positivetumors
with diﬀerent levels of EGFR expression (markedly stronger
expression in the third patient), and no bandshifts in KRAS
codons 12 and 13 were identiﬁed. All patients were found to
have “wild-” type KRAS.
4.Discussion
In all three cases, we were able to show variable disease-
free survival (from 8 to 24 weeks) after all recommended
regimens for advanced ACC had failed. This wide range
may be attributed to diﬀerent KRAS/EGFRexpression levels,
which were not routinely checked at that time. The ﬁrst
patient received EGFR-targeted therapy concurrently with
chemotherapy. However, in the third patient, the disease was
kept stable with EGFR-targeted monotherapy.
Existing data concur that EGFR is a valid therapeutic
target in ACC as most of these carcinomas are of squamous
cell histology and often strongly express EGFR. Its inhibition
seems to result in favorable tumor growth changes [11].
Most interestingly, Paliga et al. showed that squamous cell
anal canal carcinoma lacks the most common K-ras and
EGFR mutations, suggesting that cetuximab may enhance
radiosensitivity. The investigators evaluated the mutation
status of KRAS exon 2 and EGFR exon 19 and 21 in 95
tumor biopsies before treatment. They found that KRAS
exon 2 mutations and EGFR exon 19 mutations were absent
in all 95 samples. Only 3 of the samples scored positive for
EGFR exon 21 [14]. Another important study was the one
conducted by Van Damme et al. [15]. They reported absence
of Kras (exon 2) and EGFR mutations (exon 18, 20) in ACC.
EGFR expression was present in 83.7% of interpretable cases
whereas there was no EGFR ampliﬁcation. They concludedJournal of Oncology 3
Table 1: Details on the treatment of the three ACC patients receiving anti-EGFR agents.
Pt Location at
diagnosis 1st line Rec site TTP
(wks) 2nd line Rec site TTP
(wks) 3rd line Rec site TTP
(wks)
Treatment
after
anti-EGFR
agent
1
Anorectal
junction–
iliac lymph
nodes
Cis-5-FU-
RT
Abdominal,
inguinal LN 5
Cetux-
MMC—10
courses (week
12:MMC
discontinued)
Left
inguinal
mass
20 Cetux-Iri
(11 courses)
inguinal
LN 22
RT-modiﬁed
FOLFOX-7—
the patient
died 3
months later
2
Rectum,
liver,
abdominal
LN, bones
5-FU-
MMC L i v e r 6 C i sp l u sI r i Liver, bone
metastases 8 Cetux
(8 courses)
Skeletal
pain
increased
8
Palliative RT
for bone
pain–no PD
visible in
scanning or
CT–patient
did not wish
to continue
treatment
3
Anal
sphincter
T3N0M0
MMC,
5-FU, and
RT
Abdominal
lymph
nodes
81 FOLFOX Abdominal
LN 5
Panitumumab
(after HSR to
cetuximab)
(12 courses)
Local
recurrence 6R T
Cetux:cetuximab,Cis:cisplatin,CT: computedtomography scans,HSR:hypersensitivityreaction, Iri:irinotecan, LN: lymphnodes,MMC: mitomycinC,PD:
disease progression, Rec site: site of recurrence, RT: radiotherapy, wks: weeks.
that EGFR and KAS mutation analysis is not useful as a
screening method for testing for sensitivity to anti-EGFR
treatment in ACC. It is important to point out that the
high expression of EGFR does not mean that the gene is
functioning correctly, as it may still be mutated and its
downstream pathway may be malfunctioning [15]. Based
on the above, EGFR treatment was administered to our
3 patients without any information regarding EGFR and
KRAS status and these were retrospectively tested. However,
we must note that EGFR has also been found overexpressed
in breast, renal, and ovarian cancer, but no EGFR targeting
treatment has been found active in these malignancies
[16]. Furthermore, ACC studies on the use of other EGFR
targeting molecules, such as erlotinib and geﬁtinib, are very
limited, possibly because of lack of EGFR somatic mutations
in ACC and great toxicity shown in phase I trials [17].
As is thecase with refractory EGFR-expressing metastatic
colorectal cancer, EGFR inhibitors should only be used in
patients with nonmutated (wild-type) KRAS. This was also
shown in the Lukan et al. study: two out of seven patients
harbored KRAS mutations, and these were the ones with
progressive disease receiving cetuximab. In the remaining 5
patients, there was partial remission, minor remission, or
no change lasting ≥6 months after previous rapid tumor
progression [18].
Furtherquestionsariseastowhetheracombinationther-
apy with EGFR inhibitors would be most beneﬁcial and
which exact combination would be more appropriate. Phan
and Hoﬀ were the ﬁrst to report the case of a female pa-
tient with refractory anal cancer who achieved excellent
response with the combination of cetuximab and irinotecan
after disease progression with irinotecan monotherapy [19].
Ourﬁrst patientconcurrentlyreceivedmitomycin/irinotecan
and experienced the longest disease-free progression. This
combination was used on the basis of previous data
regarding activity of this regimen. The com- bined use of
cetuximab and mitomycin has been found more eﬀective
than cetuximab monotherapy in cytotoxicity assays con-
ducted in vitro, suggesting synergy between the two
agents [20]. Combined intraperitoneal chemotherapy of
panitumumab, mitomycin-C, and irinotecan also showed
eﬃcacy in colorectal carcinomatosis in vivo [21]. There is an
ongoing phase II trial studying the use of the combination
of cetuximab, irinitecan and mitomycin of colorectal cancer
[22]. In our ﬁrst case, cetuximab was originally combined
solely with mitomycin, and irinotecan was not immediately
added, as we anticipated possible increased toxicity. The
patient did actually experience hemolytic-uremic syndrome,
but the prolonged disease-free survival was notable. This
was also initially observed in irinotecan-refractory colorectal
cancer: the addition of cetuximab increased response rates as
compared to rates observed with monotherapy (22.9 percent
versus 10.8 percent) [23]. A randomized phase III trial that
concerned locoregionally advanced head and neck cancer
revealed survival beneﬁt with concurrent use of cetuximab
and radiation [24].
The third case is the one that shows the beneﬁt from
anti-EGFR agents more clearly. Panitumumab is a fully
human monoclonal antibody that constitutes an important
agent in the treatment of colorectal cancer. It seems that it
exerts its antitumor activity with a diﬀerent mechanism than
cetuximab and it is associated with far less hypersensitivity4 Journal of Oncology
reactions than the latter [25]. Rash grade 2 was observed
in the ﬁrst and second case, and rash grade 3 was reported
in case 3. These ﬁndings correlate with studies already
published that support that the rash severity can be used
as a predictive marker of response to cetuximab [26]a n d
panitumumab [27]t r e a t m e n t .
Inthisstudy,wedidnotperformany screeningtechnique
to study the possible infection of the neoplasms with human
papillomavirus (HPV). However, we should note that there
are data supporting a correlation between oncogenic HPV
and EGFR expression. In the Walker et al. study [28],
96% of invasive HPV-infected squamous ACC displayed
strong membrane immunoreactivity to EGFR expression,
further supporting the possible role of EGFR inhibitors in
ACC treatment. They also showed that HIV-positive status
contributes in augmenting EGFR expression levels that are
involved in carcinogenesis. Rare cases of ACC also have a
spindle cell component, especially when diﬀerentiation is
poor, and exclusion of anal melanoma or primary gastroin-
testinal mesenchymal tumour may be required [29]. EGFR
expression seems to diﬀer signiﬁcantly between spindle and
epithelioid cells, as has been shown in vitro as well as in
human studies [30], and this should also be taken into
account when administering anti-EGFR treatment.
We should point out that in the three cases described
above the patients received completely diﬀerent EGFR-
targeting regimens. The disease course in all three suggested
that anti-EGFR agents are eﬀective in ACC, but studies
need to be performed to examine their usefulness as
monotherapy in ACC salvage therapy as well as in speciﬁc
combinations with cytotoxic agents and radiation therapy as
ﬁrst-line treatment. Large randomized studies are necessary
in order to establish protocols. These trials must also include
assessment of EGFR and KRAS mutations of the tissue
specimens. Conformed.
Disclosure
Patient details have been removed to ensure anonymity. A
consent form has been signed by close relatives of all three
patients. Helsinki declaration was conformed.
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